Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Computed Tomography | Research

Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative ¹⁸F-FDG PET-CT in breast cancer: a retrospective cross-sectional study

Authors: Keunyoung Kim, In-Joo Kim, Kyoungjune Pak, Taewoo Kang, Young Mi Seol, Young Jin Choi, Hyojeong Kim

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

This study aimed to evaluate the potential of metabolic activity of the psoas muscle measured by ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography to predict treatment outcomes in patients with resectable breast cancer.

Methods

The medical records of 288 patients who had undergone surgical resection for stages I–III invasive ductal carcinoma of the breast between January 2014 and December 2014 in Pusan National University Hospital were reviewed. The standardized uptake values (SUVs) of the bilateral psoas muscle were normalized using the mean SUV of the liver. SUVRmax was calculated as the ratio of the maximum SUV of the average bilateral psoas muscle to the mean SUV of the liver. SUVRmean was calculated as the ratio of the mean SUV of the bilateral psoas muscle to the mean SUV of the liver.

Results

Univariate analyses identified a higher T stage, higher N stage, estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, triple-negative breast cancer, mastectomy (rather than breast-conserving surgery), SUVRmean > 0.464, and SUVRmax > 0.565 as significant adverse factors for disease-free survival (DFS). Multivariate Cox regression analysis revealed that N3 stage (hazard ratio [HR] = 5.347, P = 0.031) was an independent factor for recurrence. An SUVRmax > 0.565 (HR = 4.987, P = 0.050) seemed to have a correlation with shorter DFS.

Conclusions

A higher SUVRmax of the psoas muscle, which could be a surrogate marker of insulin resistance, showed strong potential as an independent prognostic factor for recurrence in patients with resectable breast cancer.

Available only for authorised users

Amin MN, Hussain MS, Sarwar MS, Rahman Moghal MM, Das A, Hossain MZ, et al. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab Syndr. 2019;13(2):1213–24. https://doi.org/10.1016/j.dsx.2019.01.041.CrossRefPubMed

Goodwin PJ. Obesity, insulin resistance and breast cancer outcomes. Breast. 2015;24(Suppl 2):S56–9. https://doi.org/10.1016/j.breast.2015.07.014.CrossRefPubMed

DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys. 1979;237(3):E214–23. https://doi.org/10.1152/ajpendo.1979.237.3.E214.CrossRef

DeFronzo RA, Ferrannini E, Sato Y, Felig P, Wahren J. Synergistic interaction between exercise and insulin on peripheral glucose uptake. J Clin Invest. 1981;68(6):1468–74. https://doi.org/10.1172/JCI110399.CrossRefPubMedPubMedCentral

Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Phys. 1988;255(6 Pt 1):E769–74. https://doi.org/10.1152/ajpendo.1988.255.6.E769.CrossRef

Yokoyama I, Inoue Y, Moritan T, Ohtomo K, Nagai R. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET. J Nucl Med. 2003;44(10):1592–8.PubMed

Kelley DE, Price JC, Cobelli C. Assessing skeletal muscle glucose metabolism with positron emission tomography. IUBMB Life. 2001;52(6):279–84. https://doi.org/10.1080/152165401317291129.CrossRefPubMed

Yokoyama I, Yonekura K, Ohtake T, Kawamura H, Matsumoto A, Inoue Y, et al. Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxyglucose uptake in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2000;7(3):242–8. https://doi.org/10.1016/S1071-3581(00)70013-4.CrossRefPubMed

Goodpaster BH, Bertoldo A, Ng JM, Azuma K, Pencek RR, Kelley C, et al. Interactions among glucose delivery, transport, and phosphorylation that underlie skeletal muscle insulin resistance in obesity and type 2 diabetes: studies with dynamic PET imaging. Diabetes. 2014;63(3):1058–68. https://doi.org/10.2337/db13-1249.CrossRefPubMedPubMedCentral

10.

Kim JY, Jun DW, Choi J, Nam E, Son D, Choi YY. Psoas muscle fluorine-18-labelled fluoro-2-deoxy-d-glucose uptake associated with the incidence of existing and incipient metabolic derangement. J Cachexia Sarcopenia Muscle. 2019;10(4):894–902. https://doi.org/10.1002/jcsm.12430.CrossRefPubMedPubMedCentral

11.

Nam S, Park S, Park HS, Kim S, Kim JY, Kim SI. Association between insulin resistance and luminal B subtype breast Cancer in postmenopausal women. Medicine (Baltimore). 2016;95(9):e2825. https://doi.org/10.1097/MD.0000000000002825.CrossRef

12.

Iwase T, Sangai T, Fujimoto H, Sawabe Y, Matsushita K, Nagashima K, et al. Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer. Breast Cancer Res Treat. 2020;179(2):435–43. https://doi.org/10.1007/s10549-019-05467-7.CrossRefPubMed

13.

Gallagher EJ, Fei K, Feldman SM, Port E, Friedman NB, Boolbol SK, et al. Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. Breast Cancer Res. 2020;22(1):40. https://doi.org/10.1186/s13058-020-01281-y.CrossRefPubMedPubMedCentral

14.

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast Cancer-major changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303. https://doi.org/10.3322/caac.21393.CrossRefPubMed

15.

Park J, Chang KJ, Seo YS, Byun BH, Choi JH, Moon H, et al. Tumor SUVmax normalized to liver uptake on (18)F-FDG PET/CT predicts the pathologic complete response after neoadjuvant Chemoradiotherapy in locally advanced rectal Cancer. Nucl Med Mol Imaging. 2014;48(4):295–302. https://doi.org/10.1007/s13139-014-0289-x.CrossRefPubMedPubMedCentral

16.

Zhou C, Foster B, Hagge R, Foster C, Lenchik L, Chaudhari AJ, et al. Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with (18)F-FDG PET/CT muscle metrics. Ann Nucl Med. 2020;34(3):174–81. https://doi.org/10.1007/s12149-019-01429-7.CrossRefPubMed

17.

Copeland GP, Leinster SJ, Davis JC, Hipkin LJ. Insulin resistance in patients with colorectal cancer. Br J Surg. 1987;74(11):1031–5. https://doi.org/10.1002/bjs.1800741124.CrossRefPubMed

18.

Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr. 2012;31(5):765–73. https://doi.org/10.1016/j.clnu.2012.05.003.CrossRefPubMed

19.

Pisters PW, Cersosimo E, Rogatko A, Brennan MF. Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery. 1992;111(3):301–10.PubMed

20.

Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition. 2001;17(7):590–3. https://doi.org/10.1016/S0899-9007(01)00561-5.CrossRefPubMed

21.

Yoshikawa T, Noguchi Y, Matsumoto A. Effects of tumor removal and body weight loss on insulin resistance in patients with cancer. Surgery. 1994;116(1):62–6.PubMed

22.

Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80(8):1047–50. https://doi.org/10.1002/bjs.1800800841.CrossRefPubMed

Title: Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative 18F-FDG PET-CT in breast cancer: a retrospective cross-sectional study
Authors: Keunyoung Kim
In-Joo Kim
Kyoungjune Pak
Taewoo Kang
Young Mi Seol
Young Jin Choi
Hyojeong Kim
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Computed Tomography
Computed Tomography
Breast Cancer
Insulins
Breast Cancer
Positron Emission Tomography
Insulins
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08886-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis

Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma

Robust expression of LINE-1 retrotransposon encoded proteins in oral squamous cell carcinoma

SOX14 hypermethylation as a tumour biomarker in cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer